Publications

Publications

320 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period from
to

Enter a start and/or end date here, using the following format: DD-MM-YYYY.

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by: Date / Relevance

GVS advice mexiletine (Namuscla®)

Zorginstituut Nederland has completed its assessment whether the product mexiletine (Namuscla®) is interchangeable with another ...

Report | 13-01-2021

Advice on a potential candidate for conditional inclusion of rhPTH 1-84 (Natpar®) in chronic hypoparathyroidism

Zorginstituut Nederland recommends the minister of Medical Care that rhPTH 1-84 (Natpar®) be designated as a potential candidate ...

Letter | 21-12-2020

GVS advice concerning romosozumab (Evenity®) for the treatment of severe osteoporosis

Zorginstituut Nederland has completed its assessment whether romosozumab (Evenity®) is interchangeable with a product that is ...

Report | 16-12-2020

GVS assessment of amikacin liposome inhalation suspension (Arikayce® liposomal) for the treatment of NTM lung infections

Zorginstituut Nederland has completed its assessment whether amikacin liposome inhalation suspension (Arikayce® liposomal) can be ...

Report | 15-12-2020

GVS assessment - extension of further conditions for nintedanib (Ofev®)

Zorginstituut Nederland has completed its assessment of the possible extension of the further conditions for nintedanib (Ofev®) ...

Report | 15-12-2020

Package advice polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab (Pola-BR) for the treatment of r/r DLBCL

Zorginstituut Nederland has completed its assessment whether polatuzumab vedotin (Polivy®) in combination with bendamustine and ...

Report | 10-12-2020

GVS assessment of tafamidis (Vyndaqel®) for the treatment of wild-type or hereditary transthyretin amyloidosis

Zorginstituut Nederland has completed its assessment whether tafamidis (Vyndaqel®) for the treatment of wild-type or hereditary ...

Report | 03-12-2020

Advice on a potential candidate for conditional inclusion of ataluren (Translarna®) for Duchenne's muscular dystrophy

Zorginstituut Nederland recommends that ataluren be designated as a potential candidate for conditional inclusion. Ataluren is ...

Letter | 24-11-2020

GVS advice concerning siponimod (Mayzent®) for the treatment of secondary progressive multiple sclerosis

Zorginstituut Nederland has completed its assessment whether siponimod (Mayzent®) is interchangeable with a product that is ...

Report | 16-11-2020

Package advice venetoclax (Venclyxto®) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)

Zorginstituut Nederland has completed its assessment whether venetoclax (Venclyxto®) in combination with obinutuzumab for the ...

Report | 16-11-2020